» Articles » PMID: 27648045

Anti Mullerian Hormone: Ovarian Response Indicator in Young Patients Receiving Long GnRH Agonist Protocol for Ovarian Stimulation

Overview
Journal Pak J Med Sci
Specialty General Medicine
Date 2016 Sep 21
PMID 27648045
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. We explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population.

Methods: This retrospective analysis compiled data of 166 females, receiving ICSI treatment from June 2014 to March 2015. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.

Results: Higher discriminatory power of AMH (AUROC; 0.771; p < 0.05) was seen in comparison to FSH (0.692; p < 0.05) and AFC (0.690; p < 0.01). AMH reported strongest association with oocyte retrieved (odds ratio of 15.06). Subgroup analysis reported 68.6 % risk of bad response with AMH levels of less than 1.37ng/ml. This association was observed more significant in young infertile patients <35 year of age (r=0.245; p=0.012) versus older population >35 year (r=0.169; p>0.05).

Conclusion: Our study reaffirms that serum AMH correlates well with oocytes retrieved, particularly in females younger than 35 years. We suggest incorporation of AMH in baseline assessment of infertile females, who are falsely advised to postpone interventions based on their age and normal FSH levels.

Citing Articles

Correlation of Serum Anti-Mullerian Hormone with Ovarian Follicle Output Rate in Infertile Females: A Clomiphene Citrate Challenge Test.

Fatima S, Naqvi Q, Tauseef A, Qamar M, Khan Q, Akram T Cureus. 2020; 12(5):e8032.

PMID: 32528768 PMC: 7282373. DOI: 10.7759/cureus.8032.


Predicting the outcome of different protocols of in vitro fertilization with anti-Muüllerian hormone levels in patients with polycystic ovary syndrome.

Chen Y, Ye B, Yang X, Zheng J, Lin J, Zhao J J Int Med Res. 2017; 45(3):1138-1147.

PMID: 28449632 PMC: 5536432. DOI: 10.1177/0300060517704140.

References
1.
Jamil Z, Fatima S, Ahmed K, Malik R . Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers. Dis Markers. 2016; 2016:5246217. PMC: 4764725. DOI: 10.1155/2016/5246217. View

2.
Barad D, Weghofer A, Gleicher N . Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009; 91(4 Suppl):1553-5. DOI: 10.1016/j.fertnstert.2008.09.069. View

3.
Broer S, Dolleman M, Opmeer B, Fauser B, Mol B, Broekmans F . AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2010; 17(1):46-54. DOI: 10.1093/humupd/dmq034. View

4.
Hehenkamp W, Looman C, Themmen A, de Jong F, Te Velde E, Broekmans F . Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91(10):4057-63. DOI: 10.1210/jc.2006-0331. View

5.
Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S . Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013; 5(185):185ra62. DOI: 10.1126/scitranslmed.3005402. View